Allison C, Pratt J A
Department of Physiology and Pharmacology, Strathclyde Institute for Biomedical Sciences, University of Strathclyde, Taylor Street, G4 ONR, Glasgow, UK.
Pharmacol Ther. 2003 May;98(2):171-95. doi: 10.1016/s0163-7258(03)00029-9.
Knowledge of the neural mechanisms underlying the development of benzodiazepine (BZ) dependence remains incomplete. The gamma-aminobutyric acid (GABA(A)) receptor, being the main locus of BZ action, has been the main focus to date in studies performed to elucidate the neuroadaptive processes underlying BZ tolerance and withdrawal in preclinical studies. Despite this intensive effort, however, no clear consensus has been reached on the exact contribution of neuroadaptive processes at the level of the GABA(A) receptor to the development of BZ tolerance and withdrawal. It is likely that changes at the level of this receptor are inadequate in themselves as an explanation of these neuroadaptive processes and that neuroadaptations in other receptor systems are important in the development of BZ dependence. In particular, it has been hypothesised that as part of compensatory mechanisms to diazepam-induced chronic enhancement of GABAergic inhibition, excitatory mechanisms (including the glutamatergic system) become more sensitive [Behav. Pharmacol. 6 (1995) 425], conceivably contributing to BZ tolerance development and/or expression of withdrawal symptoms on cessation of treatment, including increased anxiety and seizure activity. Glutamate is a key candidate for changes in excitatory transmission mechanisms and BZ dependence, (1) since there are defined neuroanatomical relationships between glutamatergic and GABAergic neurons in the CNS and (2) because of the pivotal role of glutamatergic neurotransmission in mediating many forms of synaptic plasticity in the CNS, such as long-term potentiation and kindling events. Thus, it is highly possible that glutamatergic processes are also involved in the neuroadaptive processes in drug dependence, which can conceivably be considered as a form of synaptic plasticity. This review provides an overview of studies investigating changes in the GABAergic and glutamatergic systems in the brain associated with BZ dependence, with particular attention to the possible differential involvement of N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors in these processes.
关于苯二氮䓬(BZ)依赖形成的神经机制的了解仍不完整。γ-氨基丁酸(GABA(A))受体作为BZ作用的主要位点,是迄今为止临床前研究中阐明BZ耐受性和戒断潜在神经适应性过程的主要焦点。然而,尽管进行了大量研究,但对于GABA(A)受体水平的神经适应性过程对BZ耐受性和戒断形成的确切作用,尚未达成明确共识。该受体水平的变化本身可能不足以解释这些神经适应性过程,其他受体系统中的神经适应性变化在BZ依赖形成中可能也很重要。特别是,有人提出,作为对安定诱导的GABA能抑制慢性增强的补偿机制的一部分,兴奋性机制(包括谷氨酸能系统)变得更加敏感[行为药理学6(1995)425],这可能导致BZ耐受性的发展和/或治疗停止时戒断症状的表现,包括焦虑增加和癫痫活动。谷氨酸是兴奋性传递机制变化和BZ依赖的关键候选者,(1)因为中枢神经系统中谷氨酸能和GABA能神经元之间存在明确的神经解剖学关系,(2)因为谷氨酸能神经传递在介导中枢神经系统中多种形式的突触可塑性(如长时程增强和点燃事件)中起关键作用。因此,谷氨酸能过程很可能也参与了药物依赖中的神经适应性过程,这可以被认为是一种突触可塑性形式。本综述概述了研究大脑中与BZ依赖相关的GABA能和谷氨酸能系统变化的研究,特别关注N-甲基-D-天冬氨酸和α-氨基-3-羟基-5-甲基-4-异恶唑丙酸受体在这些过程中可能的不同参与情况。